# Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/neoadjuvant-and-adjuvant-therapy-for-resectable-hepatocellular-carcinoma-review/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jonathan D. Schwartz,Myron Schwartz,John Mandeli,Max W. Sung |
| Citations | 256 |
| DOI | 10.1016/s1470-2045(02)00873-2 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2132478764 |
| PMID | 12372721 |
| Type | article |
| Year | 2002 |

## Paper authors

- [Jonathan D. Schwartz](https://scholariq.org/researchers/jonathan-d-schwartz/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Viral-associated cancers and disorders](https://scholariq.org/topics/viral-associated-cancers-and-disorders/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.